Ebastine for adults with diarrhea-predominant IBS
Official title: Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
Run by Dhaka Medical College · NCT07114055 · Data updated 2026-11-12
This will test whether taking ebastine at night helps adults with diarrhea-predominant IBS reduce their symptoms compared with a placebo.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Dhaka Medical College Academic / other |
| Locations | 1 site (Dhaka) |
| Status | Recruiting |
| Started | August 15, 2025 |
| Main results expected | July 2026 |
| Study ends | July 2026 |
| Registry record updated | August 20, 2025 |
| Trial ID | NCT07114055 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older who meet Rome IV criteria for diarrhea-predominant IBS, are not pregnant or lactating, and do not have alarm signs or major gastrointestinal or uncontrolled endocrine diseases.
✕Probably not a fit
People with alarm features, prior major GI surgery, uncontrolled diabetes or thyroid disease, pregnant or breastfeeding women, vehicle/mechanical/aerial operators, or those with substance abuse are excluded and would not be expected to benefit from this tested approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2/3 interventional trial compares nightly ebastine 20 mg to a matching placebo in adults who meet Rome IV criteria for diarrhea-predominant IBS. Participants take study medication once daily for 8 weeks alongside lifestyle modifications and are evaluated at baseline, week 4, and week 8 using the IBS Symptom Severity Score (IBS-SSS). Patient-reported adverse events are recorded throughout the treatment period to monitor safety. The study is conducted at Dhaka Medical College and enrolls adults aged 18 and over without alarm features or major comorbid conditions.
Why it matters
Potential benefit: If successful, ebastine could provide a new medication option to reduce diarrhea and abdominal symptoms in people with IBS-D.
How similar studies have gone: Using an antihistamine like ebastine for IBS-D is a relatively novel approach with limited prior clinical evidence supporting benefit.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria * Age 18 and above * Patients who meet the Rome IV criteria for IBS-D. Exclusion criteria * Presence of alarm features: anemia, weight loss, per rectal bleeding, nocturnal frequency, and family history of colonic cancer * History of major gastrointestinal surgery * Medical disease that affect the digestive system, such as uncontrolled diabetes, hyperthyroidism, hypothyroidism * Pregnant and lactating women * Vehicle drivers, mechanical operators and aerial operators * Drug abuse or alcohol abuse
Where it's running
-
Dhaka Medical College
Dhaka, Bangladesh Recruiting
Study contacts
- Study coordinator: Md. Hazrat Ali, MBBS
- Email: mhalirmc45@gmail.com
- Phone: +8801710725424
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Kimchi powder for gut health in adults with IBS-D
This study tests whether kimchi powder can improve gut health in adults with diarrhea-predominant IBS over 8 weeks, compared with a placebo.
-
Ferric citrate for iron deficiency anemia in pregnancy
This trial compares ferric citrate to ferrous fumarate to see if the iron pill works better and is easier to tolerate for pregnant people in the second trimester with moderate to severe iron deficiency anemia.
-
Baclofen for adults with GERD symptoms not helped by PPIs.
This trial will test whether adding baclofen to usual treatment helps adults whose GERD symptoms persist despite taking PPIs.
-
Amitriptyline versus Trifluoperazine for functional dyspepsia
This trial will test whether adding low‑dose amitriptyline or trifluoperazine to standard treatment helps adults with functional dyspepsia feel better over 8 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.